Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Covington
Julphar
Novartis
Johnson and Johnson
Daiichi Sankyo
Queensland Health
Baxter
Merck
Moodys

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,410,054

« Back to Dashboard

Which drugs does patent 6,410,054 protect, and when does it expire?

Patent 6,410,054 protects INSPRA and is included in one NDA.

Protection for INSPRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-seven countries.
Summary for Patent: 6,410,054
Title: Immediate release eplerenone compositions
Abstract:The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
Inventor(s): Thosar; Shilpa S. (Des Plaines, IL), Gokhale; Rajeev D. (Waukegan, IL), Tolbert; Dwain S. (Wadsworth, IL)
Assignee: G. D. Searle & Co. (Skokie, IL)
Application Number:09/456,614
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 6,410,054

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,410,054

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,495,165 Eplerenone compositions having improved bioavailability ➤ Try a Free Trial
6,592,902 Controlled release eplerenone compositions ➤ Try a Free Trial
6,863,902 Immediate release eplerenone compositions ➤ Try a Free Trial
7,157,101 Micronized eplerenone compositions ➤ Try a Free Trial
6,534,093 Immediate release eplerenone compositions ➤ Try a Free Trial
6,558,707 Immediate release eplerenone compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,410,054

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 028982 ➤ Try a Free Trial
Austria 249223 ➤ Try a Free Trial
Australia 1936800 ➤ Try a Free Trial
Australia 763166 ➤ Try a Free Trial
Brazil 9915964 ➤ Try a Free Trial
Canada 2326842 ➤ Try a Free Trial
China 1230179 ➤ Try a Free Trial
China 1329494 ➤ Try a Free Trial
Czech Republic 20011942 ➤ Try a Free Trial
Germany 69911240 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chubb
Chinese Patent Office
Farmers Insurance
Deloitte
Baxter
Boehringer Ingelheim
UBS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot